Sugi Predict

Sugi Predict / Targets / YARS1

YARS1

Tyrosine--tRNA ligase, cytoplasmic · P54577 · YARS1 on Sugi Atlas →

2,612 patent compounds predicted against YARS1, 2,113 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL179024 SCHEMBL179024 0.73 2/20
Levodopa Levodopa (SCHEMBL1663799) 0.61 2/20
Levodopa Levodopa (SCHEMBL4120877) 0.61 2/20
SCHEMBL1574158 SCHEMBL1574158 0.60 2/20
SCHEMBL1574161 SCHEMBL1574161 0.60 2/20
SCHEMBL238987 SCHEMBL238987 0.59 2/20
SCHEMBL238988 SCHEMBL238988 0.59 2/20
SCHEMBL4018493 SCHEMBL4018493 0.59 2/20
SCHEMBL4018497 SCHEMBL4018497 0.59 2/20
SCHEMBL678158 SCHEMBL678158 0.57 2/20
SCHEMBL678159 SCHEMBL678159 0.57 2/20
SCHEMBL7559848 SCHEMBL7559848 0.57 2/20
SCHEMBL7149290 SCHEMBL7149290 0.56 2/20
SCHEMBL7149294 SCHEMBL7149294 0.56 2/20
Levodopa Levodopa (SCHEMBL8599507) 0.56 2/20
SCHEMBL5887796 SCHEMBL5887796 0.55 2/20
SCHEMBL5887814 SCHEMBL5887814 0.55 2/20
SCHEMBL5887928 SCHEMBL5887928 0.55 2/20
SCHEMBL8529219 SCHEMBL8529219 0.55 2/20
SCHEMBL8529222 SCHEMBL8529222 0.55 2/20

Clinical trials — most relevant to YARS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients PHASE2COMPLETED
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS) PHASE1/PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma PHASE1WITHDRAWN
Nucleoside Therapy in Patients With Telomere Biology Disorders PHASE1RECRUITING
Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients EARLY_PHASE1COMPLETED
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
Genetic Studies Spermatogenic Failure nanCOMPLETED
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
Immunophenotyping and Xist Gene in AML nanUNKNOWN
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
Does Preimplantation Genetic Diagnosis for Sex Selection Affect the Pregnancy and Miscarriage Rates in Women With an Expected Good Ovarian Response Undergoing IVF/ICSI Cycles? nanCOMPLETED
Genomic Study of Congenital Malformation nanUNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Genetic Analysis of Fraser Syndrome and Fryns Syndrome nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Research of Therapeutic Targets in the Frame of Nephronophthisis and Renal Associated Ciliopathies nanRECRUITING
Genomic Predictors of Recurrent Pregnancy Loss nanRECRUITING
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin) nanWITHDRAWN
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis nanACTIVE_NOT_RECRUITING
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Oxidative Stress in Testicular Tissue Before and After Cryopreservation nanCOMPLETED
Body Awareness and Aerobic Exercise: Telomere Impact nanCOMPLETED
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a YARS1 binder may also engage these)

ProteinNameSimilarity
Q5R8T5 — 1.000 Q5R8T5 →
Q4KM49 — 1.000 Q4KM49 →
Q91WQ3 — 1.000 Q91WQ3 →
Q29465 — 0.997 Q29465 →
Q6TGS6 — 0.992 Q6TGS6 →
Q5ZJ08 — 0.991 Q5ZJ08 →
Q6DIJ1 — 0.986 Q6DIJ1 →
Q7ZX51 — 0.985 Q7ZX51 →
Q8S9J2 — 0.964 Q8S9J2 →
LARS1 Leucine--tRNA ligase, cytoplasmic 0.958 landscape →
Q5R614 — 0.957 Q5R614 →
P36871 — 0.955 P36871 →
Q08DP0 — 0.954 Q08DP0 →
A0A0K9RL25 — 0.953 A0A0K9RL25 →
Q4R5E4 — 0.953 Q4R5E4 →
P00949 — 0.953 P00949 →
Q8BMJ2 — 0.952 Q8BMJ2 →
Q9ZSQ4 — 0.951 Q9ZSQ4 →
Q9D0F9 — 0.951 Q9D0F9 →
O49299 — 0.950 O49299 →
Q9SGC1 — 0.950 Q9SGC1 →
Q9M4G4 — 0.949 Q9M4G4 →
Q9SNX2 — 0.949 Q9SNX2 →
P38652 — 0.949 P38652 →
P93805 — 0.949 P93805 →
P93804 — 0.949 P93804 →
Q9SM60 — 0.948 Q9SM60 →
P93262 — 0.948 P93262 →
Q004B5 — 0.948 Q004B5 →
Q8C878 — 0.947 Q8C878 →